The claims of the issued patent cover the Antisenilin ‘free-end specific’ antibodies that bind to beta amyloid and use of the antibodies in preventing or inhibiting the progression of Alzheimer’s disease.
The technology is designed to promote the clearance of beta amyloid which accumulates to reach toxic concentrations in the brains of Alzheimer’s patients while reducing the potential for adverse side-effects.
Daniel Chain, chairman and CEO of Intellect Neurosciences, said: “The grant of the European patent represents an important milestone with respect to our strategy, which is to leverage our monoclonal antibody patent estate by licensing it to a number of major pharmaceutical companies with drug candidates in clinical development.
“The grant of the patent triggers a milestone payment under our contract with Wyeth and Elan and provides us the potential opportunity to receive royalties based on product sales in Europe, in addition to Japan and other countries.”